Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Acesion Pharma APS

www.acesionpharma.com

Latest From Acesion Pharma APS

Venture Funding Deals: Innovent Sets Financing Record In China

The firm’s $260m Series D is the largest ever for biopharma in China and one of the biggest of the year worldwide; other notable financings go to Biohaven, Kymab and Magenta. Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced October through early December.

StartUps and SMEs Financing

Execs On The Move, May 2016

Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

BioPharmaceutical Medical Device

Atrial Fibrillation Agents: Better Drugs For The Arrhythmic Heart

Improvements in targeting the sources of aberrant cardiac rhythms may open the heart up to new therapies. In this issue, we profile four start-ups focused on developing treatments for AF and other arrhythimas: Acesion Pharma, ChanRx, Milestone Pharmaceuticals and Serodus.

BioPharmaceutical

Acesion Pharma APS

Denmark’s Acesion Pharma AS’ co-founders Ulrik Sørensen, now serving as CEO, and Morten Grunnet, the start-up’s CSO, both worked for over a decade at NeuroSearch AS on a target and compounds that could yield a new treatment for AF. The target is a type of calcium-activated potassium channel classified as the SK channel. Although many kinds of ion channels have been pursued as targets of AF drugs, this particular channel is novel as a drug target and no drugs have been developed against it.

BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Scandinavia
          • Denmark
  • Parent & Subsidiaries
  • Acesion Pharma APS
  • Senior Management
  • Frans S Wuite, MD, CEO
    Morten Grunnet, PhD, CSO
  • Contact Info
  • Acesion Pharma APS
    Ole Maaløes Vej 3, 2200
    Copenhagen, DK-2200
    Denmark
Advertisement
Advertisement
UsernamePublicRestriction

Register